Submission of new Drug Application for the treatment of presbyopia
Allergan, an AbbVie (NYSE: ABBV) company, announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021. Approximately 128 million adults in the U.S….

